Investigative Ophthalmology & Visual Science Cover Image for Volume 62, Issue 8
June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Use of quantitative proteomic analysis to identify potential mechanisms of neuroprotection from myeloid differentiation factor 88 (MyD88) inhibition in the retinal degeneration (rd) 10 mouse
Author Affiliations & Notes
  • Tal Carmy-Bennun
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, United States
  • Ciara Myer
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, United States
  • Sanjoy K Bhattacharya
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, United States
  • Abigail Hackam
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Tal Carmy-Bennun, None; Ciara Myer, None; Sanjoy Bhattacharya, None; Abigail Hackam, None
  • Footnotes
    Support  NIH/NEI EY026546 (ASH), and U.S. Department of Defense (WHX81-16-0715), Foundation Fighting Blindness, Research to Prevent Blindness Unrestricted Grant and an NEI Center Core Grant EY014801
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3011. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tal Carmy-Bennun, Ciara Myer, Sanjoy K Bhattacharya, Abigail Hackam; Use of quantitative proteomic analysis to identify potential mechanisms of neuroprotection from myeloid differentiation factor 88 (MyD88) inhibition in the retinal degeneration (rd) 10 mouse. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3011.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : MyD88 mediates inflammatory signaling in the retina. MyD88 inhibition delayed rod photoreceptor death in two mouse models of retinal degeneration. In this study, we performed quantitative proteomic analysis using liquid chromatography-tandem mass spectrometry iTRAQ to characterize early protein changes that may contribute to the protective effects of inhibiting MyD88 in rd10 mouse retinas.

Methods : Rd10 mice (male and female, PN day 18) were injected IP with 2 mg/Kg MyD88 inhibitor (neuroprotective dose) or control peptide (n=4 each). Retinas were collected 3 days later, proteins were extracted then trypsin digested, and incubated with 8-PLEX iTRAQ Reagents followed by analysis using Q Exactive mass spectrometer. Proteins were identified and quantified using Proteome Discoverer 2.2 software, bioinformatics enrichment analysis used PANTHER v.15.0 and interaction networks used the STRING database v.11. QPCR was used to confirm gene expression.

Results : A total of 332 proteins were identified with high (FDR<0.01) and medium confidence (FDR<0.05) with >2 unique matching peptides. Forty-two proteins were differentially expressed (fold change >1.2 or <0.83; p<0.05): 20 proteins were upregulated in the MyD88 inhibitor group and 22 were downregulated. The top biological processes were metabolic, developmental and regulation, and the top molecular functions were catalytic activity, binding and structural molecules. The upregulated proteins were enriched in crystallins, unfolded protein binding and structural molecular activity, and decreased proteins were enriched in pyrophosphatase activity, small molecule binding, and peptide biosynthesis. Notably, MyD88 inhibition led to upregulation of 7 stress-response crystallins. STRING analysis on the upregulated proteins showed 3 distinct physical interaction networks (p=1.94e-05): crystallins, cytosolic small ribosome subunit and aminopeptidase activity. Retinal expression of the crystallin genes was confirmed by QPCR.

Conclusions : This study provides a foundation for understanding molecular mechanisms regulating retinal homeostasis in rd10 mice. A novel link was identified between anti-apoptotic crystallins and MyD88 inflammatory pathway inhibition.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×